Haemonetics Co. (NYSE:HAE) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its position in shares of Haemonetics Co. (NYSE:HAE) by 0.7% during the third quarter, HoldingsChannel reports. The institutional investor owned 542,716 shares of the medical instruments supplier’s stock after selling 4,067 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Haemonetics were worth $43,624,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its stake in shares of Haemonetics by 3.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock valued at $304,000 after purchasing an additional 117 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Haemonetics by 3.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock valued at $392,000 after buying an additional 180 shares during the period. QRG Capital Management Inc. raised its position in Haemonetics by 6.9% during the 2nd quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier’s stock worth $333,000 after buying an additional 260 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Haemonetics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock worth $1,176,000 after acquiring an additional 272 shares during the period. Finally, Keene & Associates Inc. boosted its holdings in shares of Haemonetics by 3.0% in the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock valued at $818,000 after acquiring an additional 298 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

HAE has been the subject of a number of recent analyst reports. Barrington Research restated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a research report on Friday, November 8th. Needham & Company LLC reissued a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a report on Friday, November 15th. BTIG Research assumed coverage on Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price objective on the stock. Citigroup reduced their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Finally, JMP Securities restated a “market outperform” rating and issued a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Stock Down 0.5 %

HAE opened at $87.47 on Monday. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The business has a 50-day moving average of $79.99 and a two-hundred day moving average of $82.05. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The stock has a market capitalization of $4.39 billion, a price-to-earnings ratio of 36.29, a price-to-earnings-growth ratio of 1.36 and a beta of 0.32.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping the consensus estimate of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.99 earnings per share. On average, research analysts expect that Haemonetics Co. will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.